KOSDAQSemiconductors317770

Xperix

₩2,075▼ 0.72%2026-11-18 close
Market Cap
₩76.8B
Turnover
₩53,850,705
Volume
30K
Shares out.
37M
PER
—
PBR
0.8×
EPS
-₩62
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Xperix: Core Recovery Meets a Consolidation Test

Xperix sits between a recovering core identity-verification business and upfront AI and healthcare investment costs, and the consolidation of affiliate ID is the next swing factor.

  1. 1

    On a disclosed basis, 2025 revenue rose 45.7% to KRW 21.5 billion, but the company still posted an operating loss of KRW 1.41 billion and a net loss attributable to controlling shareholders of KRW 19.5 billion.

  2. 2

    Revenue peaked at KRW 7.03 billion in the fourth quarter of 2025, then fell for three straight quarters through the third quarter of 2026, when it reached KRW 5.09 billion.

  3. 3

    Net income attributable to controlling shareholders turned positive at KRW 3.07 billion in the first quarter of 2026, then narrowed to KRW 1.13 billion in the second quarter and swung to a net loss of KRW 2.66 billion in the third quarter.

  4. 4

    The company plans to bring affiliate ID into consolidation within 2026 and presents this as a driver of higher consolidated revenue and profitability.

  5. 5

    A KRW 25.5 billion convertible bond and two third-party share placements in October and November 2026 add funding pressure, and the resulting dilution is the next item to track.

02

Business structure

Xperix was founded in April 2017 and listed on KOSDAQ in August 2019 as a digital identity-verification and AI solutions company.

Its core is biometric authentication solutions, and the company's own 2025 nine-month commentary credited the resumption of electronic resident ID and e-passport issuance projects and biometric solution development for higher core-market sales.

Public-sector demand is expanding as more countries build eID systems and eIDAS-related projects proceed. The company completed its merger with subsidiary Ainut in July 2026, creating an AI solutions and infrastructure division.

That division signed a distribution agreement with Korean NPU developer FuriosaAI covering servers built on the RNGD accelerator and is co-developing an 'AI all-in-one appliance' that combines Xperix software with agentic AI.

The digital healthcare subsidiary Beoglabs is co-developing a customized digital therapeutic linked to a Hanmi Pharmaceutical obesity drug pipeline, and the company says commercialization will follow development and regulatory approval.

Affiliate ID, an intellectual property monetization business, is currently accounted for under the equity method, and Xperix plans to acquire additional shares to make it a consolidated subsidiary. Segment revenue shares are not included because no verified figures were available.

The business therefore has three strands: the core identity-verification business, the AI and healthcare growth initiatives, and IP income reflected through the equity method.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩6B-₩800M−12.8%
2025Q4₩7B₩1.1B15.0%
2026Q1₩6.7B-₩800M−12.1%
2026Q2₩5.3B-₩800M−15.4%
2026Q3₩5.1B-₩800M−16.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩15.1B₩2.8B₩3B18.7%6.5%4.8%
2023₩11.9B-₩4.2B-₩3.6B−35.1%−6.6%6.6%
2024₩14.7B-₩3.2B-₩3B−22.0%−5.3%65.6%
2025₩21.5B-₩1.4B-₩19.5B−6.6%−24.0%35.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a disclosed basis, annual revenue went from KRW 15.1 billion in 2022 to KRW 11.9 billion in 2023, a 21.0% decline, then rose 23.8% to KRW 14.7 billion in 2024 and 45.7% to KRW 21.5 billion in 2025. Revenue increased in 2024 and 2025 following the 2023 low, and 2025 was the largest year in the 2022 to 2025 period.

Operating profit fell from KRW 2.82 billion in 2022 to an operating loss of KRW 4.18 billion in 2023, followed by losses of KRW 3.25 billion in 2024 and KRW 1.41 billion in 2025, so the losses narrowed.

The operating margin moved from 18.7% in 2022 to -35.1% in 2023, then -22.0% in 2024 and -6.6% in 2025, a recovery trend.

Net income attributable to controlling shareholders fell from KRW 3.03 billion in 2022 to a net loss of KRW 3.64 billion in 2023, then KRW 3.02 billion in 2024, and widened to KRW 19.5 billion in 2025.

Net loss including non-controlling interests was KRW 20.4 billion in 2025, a different figure from the controlling-shareholder number. Operating cash flow went from KRW 2.89 billion in 2022 to negative figures in each year from 2023 through 2025.

The debt ratio was 4.8% in 2022 and 6.6% in 2023, rose to 65.6% in 2024 and fell to 35.1% in 2025, when total equity was KRW 89.9 billion, of which KRW 81.3 billion belonged to controlling shareholders.

Quarterly revenue peaked at KRW 7.03 billion in the fourth quarter of 2025 after KRW 5.96 billion in the third quarter, then declined to KRW 6.73 billion, KRW 5.26 billion and KRW 5.09 billion over the next three quarters, with the third quarter of 2026 down 14.7% year on year.

Operating profit of KRW 1.05 billion in the fourth quarter of 2025 was followed by operating losses in each quarter from the first quarter of 2026 through the third quarter, and the third-quarter loss of KRW 838 million was wider than a year earlier.

Net income attributable to controlling shareholders turned positive at KRW 3.07 billion in the first quarter of 2026.

The company attributed this to affiliate-driven equity-method gains of KRW 3.5 billion and the end of stock option expenses that had been booked over roughly two years, so this result reflects factors other than core operating recovery by the company's own account. Net losses attributable to controlling shareholders over the most recent four quarters total KRW 2.24 billion.

05

Industry analysis

Xperix's core business depends on public-sector identity verification and biometric authentication demand. According to company disclosures, demand is rising as more countries build eID systems and eIDAS-related projects continue.

The company said it plans to extend into immigration, public safety and administrative applications in response to public-sector AI transformation demand. On the AI infrastructure side, the key element is distribution of servers built on FuriosaAI's RNGD NPU, which pairs existing identity software with AI appliances.

Within the AI infrastructure investment cycle, Xperix therefore sits at an early stage, adding AI infrastructure on top of its existing business.

Affiliate ID monetizes intellectual property and is pursuing standard essential patents and expanded global licensing, a revenue model that differs in character from Xperix's identity business.

The sector classification used in this report is semiconductors, while the data provider classifies the company under IT hardware.

06

Outlook

On August 18, 2026, the company said standalone first-half operating profit turned positive at KRW 90 million. In the same announcement, first-half consolidated revenue rose 41.2% to KRW 12.0 billion, while the consolidated operating loss was KRW 1.6 billion.

The company attributed the consolidated loss to R&D and commercialization costs in new businesses including Beoglabs and Ainut.

Affiliate ID reported first-half consolidated revenue of KRW 26.2 billion, up 28.4%, according to the company, which expects ID's 2026 annual results to exceed its 2025 record of KRW 47.8 billion in revenue and KRW 11.3 billion in operating profit.

Xperix plans to acquire additional ID shares and bring ID into consolidation within 2026. The company said that in 2027 both the existing and new businesses should contribute to earnings improvement.

Commercialization of the FuriosaAI distribution business and the AI all-in-one appliance is expected to proceed in sequence. Beoglabs' digital therapeutic for obesity still requires development and regulatory approval, so no launch date has been set.

On the funding side, KRW 25.5 billion of convertible bonds (Series 6 and 7) is being used to fund the ID share acquisition, with conversion available from May 15, 2027.

In October 2026 the company decided on a third-party share placement of KRW 2.0 billion, and in November 2026 on another placement at KRW 1,908 per share.

07

Valuation

PER
—
PBR
0.8×
ROE
-2.6%
EPS
-₩62
BPS
₩2,504
Dividend per share
₩0

The price-to-book ratio is 0.83x, a level that places the share price below book value per share. Measured against controlling-shareholder equity of KRW 81.3 billion at the end of 2025, the market capitalization sits below that equity base.

PER cannot be calculated because net losses attributable to controlling shareholders have continued over the most recent four quarters. The company does not pay cash dividends, so dividend-based comparisons do not apply. The most recent third-party placement was priced at a 10% discount to the reference share price.

If ID is consolidated, the consolidated earnings structure will change, and the basis for PER would change with it. Comparisons with the historical PER range carry limited meaning because the company has been loss-making for an extended period.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Core profit direction turning

On August 18, 2026, the company said standalone first-half operating profit turned positive. Consolidated first-half revenue rose 41.2% to KRW 12.0 billion in the same announcement.

Net income attributable to controlling shareholders also turned positive at KRW 3.07 billion in the first quarter of 2026, which the company credited to new product launches and expanding domestic and overseas sales.

Plan to consolidate affiliate ID

Affiliate ID, an IP monetization business, reportedly posted record results in 2025 with revenue of KRW 47.8 billion and operating profit of KRW 11.3 billion. The company said ID's first-half 2026 consolidated revenue rose 28.4% to KRW 26.2 billion.

Xperix plans to acquire more ID shares and bring it into consolidation within 2026, which the company expects to expand consolidated revenue and profitability.

New AI and healthcare pipeline

Xperix signed a distribution agreement with FuriosaAI for RNGD-based server sales and is co-developing an AI all-in-one appliance. Its subsidiary Beoglabs is co-developing a digital therapeutic linked to a Hanmi Pharmaceutical obesity drug pipeline. The company said commercialization will follow development and regulatory approval.

09

Bear factors

Revenue declining since late 2025

Revenue peaked at KRW 7.03 billion in the fourth quarter of 2025 and then fell for three straight quarters through the third quarter of 2026. The third-quarter figure of KRW 5.09 billion was down 14.7% from a year earlier.

Operating losses have persisted over the same three quarters, and the third-quarter operating loss of KRW 838 million was wider than in the prior-year period.

Dilution from convertibles and placements

The KRW 25.5 billion Series 6 and 7 convertible bonds carry a conversion price of KRW 3,780 per share, with conversion available from May 15, 2027. A KRW 2.0 billion third-party placement was decided in October 2026, and another at KRW 1,908 per share in November 2026. Continued fundraising means dilution is accumulating.

Consolidated losses and upfront costs

The 2025 operating loss was KRW 1.41 billion, but the net loss was KRW 20.4 billion including non-controlling interests, and the loss attributable to controlling shareholders widened to KRW 19.5 billion from KRW 3.02 billion in 2024.

The company attributes consolidated operating losses to R&D and commercialization costs for new businesses. Cost burdens continue until new-business revenue becomes visible, which is a bearish factor.

10

Risk factors

Funding and dilution

Convertible bonds and third-party placements have been decided in quick succession, increasing the share count. Because conversion and issue prices are tied to share price levels, dilution scale can vary with market movements. Changes in tradable supply after the new shares list in December 2026 are another factor to monitor.

Execution of the affiliate consolidation

Acquiring additional ID shares and consolidating ID is planned for 2026, so execution and timing will determine the actual outcome. A delay would push back the expected consolidated improvement. Because the acquisition is funded by convertible bonds, debt and dilution costs run alongside the consolidation benefit.

Commercialization and regulation

The digital healthcare business still requires development and regulatory approval, so no launch date has been set. Public-sector identity and AI infrastructure revenue can move with government procurement timing and budgets.

If new-business revenue is recognized later than planned, upfront costs stay in the income statement for longer.

11

What to watch next

  1. December 9, 2026

    Scheduled listing date for the new shares from the third-party placement. The next check is how the higher share count is reflected in per-share metrics.

  2. Before December 31, 2026

    Outcome of the planned additional ID share acquisition and consolidation. The timing and method will change the structure of consolidated revenue and operating results.

  3. Before March 31, 2027

    Deadline for the 2026 annual report. The key items are the full-year operating margin relative to -6.6% in 2025 and the annual trend after three consecutive quarterly operating losses.

  4. May 15, 2027

    Deadline for the first-quarter 2027 report, which coincides with the start of conversion requests on the Series 6 convertible bonds. The next check is the scale of conversion requests alongside the direction of first-quarter operating results.

12

Overall view

Xperix's disclosed 2025 results show revenue of KRW 21.5 billion, up 45.7%, and an operating margin of -6.6%, pointing to a recovering core business.

However, the net loss attributable to controlling shareholders widened to KRW 19.5 billion, and operating losses persisted for three straight quarters from the first quarter through the third quarter of 2026, so quarterly profitability is not yet consistent.

The company attributes the first-quarter 2026 profit to equity-method gains and the end of stock option expenses, a factor separate from core operating recovery. The AI distribution and healthcare co-development remain upfront investments without a set commercialization date.

Consolidating affiliate ID, which the company identifies as central to its earnings change, is being pursued alongside a KRW 25.5 billion convertible bond and two third-party placements, so dilution is rising as well.

The price-to-book ratio of 0.83x sits below book value, while PER cannot be calculated given net losses over the last four quarters.

The next checkpoints are the full-year operating margin in the 2026 annual report, the outcome of the planned ID consolidation within 2026, and first-quarter 2027 results along with convertible conversion activity around May 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. m.etoday.co.kr
  2. supple.kr
  3. comp.wisereport.co.kr
  4. newstomato.com
  5. v.daum.net
  6. m.news.nate.com
  7. etoday.co.kr
  8. dealsite.co.kr
  9. m.news.nate.com
  10. vegannews.co.kr
  11. news.nate.com
  12. digitaltoday.co.kr
  13. news.nate.com
  14. m.news.nate.com
  15. m.news.nate.com
  16. m.news.nate.com
  17. m.news.nate.com
  18. digitaltoday.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis